Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
18.6M
-
Shares change
-
+18.6M
-
Total reported value, excl. options
-
$238M
-
Value change
-
+$238M
-
Put/Call ratio
-
0.38
-
Number of buys
-
68
-
Price
-
$12.85
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q3 2020
78 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q3 2020.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.6M shares
of 54.7M outstanding shares and own 33.9% of the company stock.
Largest 10 shareholders include Lion Point Capital, LP (2.72M shares), BOXER CAPITAL, LLC (2.4M shares), BlackRock Inc. (1.75M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.46M shares), VANGUARD GROUP INC (1.27M shares), 683 Capital Management, LLC (972K shares), Alyeska Investment Group, L.P. (932K shares), SUVRETTA CAPITAL MANAGEMENT, LLC (780K shares), Islet Management, LP (650K shares), and Bleichroeder LP (580K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.